Details of the Drug

General Information of Drug (ID: DM0QNF4)

Drug Name
TRx0237
Synonyms
951131-15-0; UNII-E79ZM68IOZ; E79ZM68IOZ; Leucomethylene Blue dihydrobromide; TRX0237 dihydrobromide; TRX 0237 dihydrobromide; TRX-0237 dihydrobromide; TRx0237(LMTX); TRX-0237 2HBr; Leukomethylene Blue dihydrobromide; Hydromethylthionine HBr(TRX0237); BCP24159; EX-A4299; Reduced methylene Blue dihydrobromide; N3,N3,N7,N7-Tetramethyl-10H-phenothiazine-3,7-diamine dihydrobromide; Leucomethylene Blue 2HBr;TRX0237 dihydrobromide;TRX 0237 dihydrobromide;TRX-0237 dihydrobromide
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 3 [1]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski):
0		 Molecular Weight 447.2
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 2
Hydrogen Bond Donor Count 3
Hydrogen Bond Acceptor Count 4
Chemical Identifiers
Formula
C16H21Br2N3S
IUPAC Name
3-N,3-N,7-N,7-N-tetramethyl-10H-phenothiazine-3,7-diamine;dihydrobromide
Canonical SMILES
CN(C)C1=CC2=C(C=C1)NC3=C(S2)C=C(C=C3)N(C)C.Br.Br
InChI
InChI=1S/C16H19N3S.2BrH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;;/h5-10,17H,1-4H3;2*1H
InChIKey
JAUPSVVTGFBHTN-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
23651551
CAS Number
951131-15-0
TTD ID
D5FSV8

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Microtubule-associated protein tau (MAPT) TTS87KH TAU_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Alzheimer disease
ICD Disease Classification 8A20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Microtubule-associated protein tau (MAPT) DTT MAPT 3.76E-06 -0.22 -0.6
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01689246) Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health.
2 Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Curr Alzheimer Res. 2020;17(3):285-296.